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THE TREATMENT OF LUPUS ERYTHEMATOSTJS
WITH MEPACRINE (ATABRINE)*
GEORGE HARVEY, M.B., Ca.B. AND THOMAS COCHRANE, B.Sc., M.D.
It is now little more than a year since Page (1) published his article on the
treatment of lupus erythematosus with mepacrine. Sommerville, Devine, and
Logan (2), Cramer and Lewis (3), Sawicky, Kanof, Silverberg, Braitman and
Kalish (4) and Wells (5) reported on cases of lupus erythematosus treated with
mepacrine (atabrine). During the past year we have used this drug in a number
of cases of this disease. Our results varied somewhat from those observed by the
above writers and we thought that it would be worth comparing our results with
mepacrine with those obtained by the use of bismuth and mapharside.
RESULTS OF TREATMENT
Table I gives the results of 20 previously untreated cases of lupus erythema-
tosus who were given mepacrine. Forty-two cases all of whom had failed to re-
spond to other forms of treatment were tried on mepacrine. Table II shows the
results of treatment by mepacrine hydrochloride in the 62 cases of lupus ery-
thematosus. Of the 62 cases 57 were typical chronic discoid lupus erythematosus,
4 were subacute cases of the disease with disseminated skin lesions and vague
general malaise—2 had arthritic joint changes—and 1 was an acute disseminated
case with widespread skin lesions, general malaise, pyrexia, albuminuria, leu-
kopenia and spleriic enlargement. The dosage of mepacrine used varied slightly
in different cases. The usual dosage was 200 mg. daily for one week and then
300 mg. for four weeks. The dose was then reduced to 200 mg. for four weeks
and then to 100 mg. daily. The exact time of the reduction period varied with
the degree of yellow staining. The duration of treatment varied from six weeks
to eighteen weeks with an average duration of twelve weeks. Staining persisted
for many weeks after withdrawal of the drug and was detectable by ifitered
ultra violet light much longer than the naked eye. The staining was most evi-
dent around the hair follicles.
From Table II it will be seen that only 12 of the 20 previously untreated
cases gave a satisfactory response to mepacrine treatment. Twenty-five of the
42 old cases showed a good response to the treatment. Three of the four subacute
cases gave an excellent result but the youngest patient who presented typical
lesions on the forehead, cheeks, nose, scalp, elbows, hands, fingers, knees, feet
and chest, associated with general malaise and vague joint pains, did not im-
prove on 200 mg. daily for ten weeks apart from the erythema of the lesions on
the forehead becoming less intense. In 2 of the 3 successfully treated subacute
cases although the skin cleared completely the arthritic joint changes were un-
altered and the B.S.R. remained high. The skin lesions recurred in two and four
months respectively after stopping treatment. The skin lesions of the one acute
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case responded well to mepacrine but she now, four months after stopping treat-
ment, shows very definite reactivity and is again on treatment.
The response to treatment in our cases did not appear to be related so closely
to the intensity of the yellow staining as was expected. In the 23 cases respond-
ing excellently to treatment 12 had moderate staining and 2 only mild staining.
Of the 37 satisfactory cases no less than 12 cases relapsed during an observation
period of from two to five months. Four of these 12 cases are now responding
slowly to a further course of treatment. A comparison is made with the above
figures and those from a series of cases treated with mapharside (3) and bismuth
(4). No cases treated with gold are included as we have not used this heavy metal
in the treatment of lupus erythematosus for many years on account of its high
toxicity. The results of the three methods of treatment are summarised in Table
III.
TABLE II
TYPE OF CASE NUMBRR
RxSLTS OP TREATMENT
Good Slight Nil
8 4 2 6
15 10 5 12
RELAPSES
4
8
REACTIONS
3
5
Fresh cases 20
Old cases 42
Total 62 23 14 7 18 12 8
TABLE III
METHOD OP TREATMENT NUMBER
RESULTS OP TREATMENT
RELAPSES REACTIONS
Excellent Good Satisfactory
Mepacrine
Bismuth
Mapharside
62
117
56
23 14 37 (59.7%)
46 40 86 (73.5%)
20 17 37 (66.2%)
12
9
5
8
3
4
To eliminate the possibility that mepacrine acted by its antimalarial properties
two other drugs, used in the treatment of malaria, were given to a small series
of cases. Chioroquine and paludrine were each used in the treatment of 10 cases
of lupus erythematosus. With chioroquine 0.15Gof chioroquine base was given
every second day for two weeks and then 0.15G daily for two weeks. The dose
was reduced to the original level for a further four to six weeks. With paludrine
O.075G was given daily for 1 week than 0.1G daily for 1 week, 0.3G daily for
1 week and finally 0.1G daily for 6 weeks. The average duration of treatment
was ten weeks. The results are tabulated in Table IV. No satisfactory results
were obtained with paludrine. Two cases cleared completely with chioroquine.
Both of these patients suffered from the disease for only a few months. One case
has relapsed subsequently but the other patient still remains cured after five
months observation. It is possible that these cases are examples of spontaneous
remission which is not unknown in lupus erythematosus.
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A 5 % mepacrine ointment and a 5 % aqueous paint were used as local treat-
ment oniy in 6 cases but there was no obvious success.
TABLE IV
METNOD OP TREATMENT NIflEBER
RESULTS OP TREATMENT
RELAPSES REACTIONS
Excellent Good Nil
Chioroquine
Paludririe
10
10
2 — 8
— — 10
1
—
—
—
COMPLICATIONS
Complications from mepacrine treatment occurred in 8 of the cases: 3 developed
typical lichenoid dermatitis, 2 had severe hyperkeratosis of the palms and soles
and 1 an acute exfoliative dermatitis. This patient and 1 of the cases of lichenoid
dermatitis were so severe as to warrant admission to the wards. Two patients
suffered from severe nausea and abdominal colic related definitely to the mep-
acrine intake. Two patients, a man and a woman, refused further treatment
after 3 weeks because of the yellow staining and 3 women refused mepacrine
because of the discoloration which they had seen in other patients. One peculiar
pseudocomplication occurred in a patient who spent seven weeks in bed with
"yellow jaundice" after a most sucessful six weeks course of mepacrine.
COMMENT
Of 62 cases of lupus erythematosus 37 responded satisfactorily to treatment
with mepacrine. Sequeira, Ingram and Brain (8) state that sixty per cent of
cases of lupus erythematosus respond to treatment. Our number of satisfactory
results (37 or 59.7%) approximates closely to that figure but differs widely from
the results obtained by Page (1) and Sommerville et al. (2). Nevertheless this
number of successes in the treatment of such a capricious disease as lupus ery-
thematosus can be regarded as satisfactory. It does not, however, make mep-
acrine the treatment of choice in this disease. This can be seen more clearly
when the results obtained with mepacrine are compared with those from bismuth
and mapharside. Mepacrine is only slightly below bismuth and mapharside in
success in treatment but when the relapses and reactions of each drug are com-
pared the differences between them become more emphasized and mepacrine
becomes inferior to the other two. Page (1) does not state the reactions he ob-
served with bismuth but remarks that they are well known. In a considerable
experience of the use of bismuth we have had no reactions. Compared with gold
we agree that mepacrine is a much more useful drug. Gold does produce an
average number of satisfactory results in lupus erythematosus but it gave toxic
reactions in no less than 22% of cases with several fatal issues (6). It has been
stated by Page (1) that only 3 cases of lichenoid dermatitis were observed in
several thousand troops receiving mepacrine. En only 62 cases we had 3 cases of
lichenoid dermatitis, 1 case of exfoliative dermatitis and 2 of hyperkeratotic
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dermatitis. Peterkin (9) is of the opinion that patients with previous skin disease
are predisposed to lichenoid dermatitis. We agree with this suggestion and we
are of the opinion that patients suffering from lupus erythematosus are unusually
liable to develop skin complications in any treatment. This theory is supported
by the dermal complications which occurred in the cases treated with mapharside.
Three cases of arsenical dermatitis arose in 56 cases of lupus erythematosus while
no skin complications have been seen in several hundred cases of syphilis treated
with mapharside by one of us.
We do not consider mepacrine our treatment of choice in lupus erythematosus.
However since it did produce an excellent result in 15 of 42 cases which had
resisted other forms of treatment and on account of the satisfactory results ob-
tained in the fresh cases we feel that there is a definite place for it in the treat-
ment of lupus erythematosus. Great care should be taken during its adminis-
tration to minimize the danger of producing a dermatitis which can last for
many months and which can cause much more disability than the original
discoid lupus erythematosus. The drug is easy to take, but control of the pa-
tient should be strict and the drug should be stopped immediately on the occur-
rence of pruritus. The yellow staining indicates that the tablets are being taken
but we feel that it masks the lesions, because as the staining appears it is difficult
to state the degree of erythema and the activity of the lesions. At first glance
many lesions seem to be healing but as the yellow stain recedes on stopping the
tablets the redness and activity resume their original intensity. We are of the
opinion that assessment of cure should not be made until the yellow staining
has been absent clinically from six to eight weeks.
We intend to try the drug further in cases of acute disseminated lupus ery-
thematosus. The good response of the subacute and acute cases resembles the
action of ACTH in these cases but the joint manifestations did not improve.
Currie (10) reported to us that he had no success with mepacrine in his clinic
for rheumatoid arthritis. This would appear to be evidence that mepacrine does
not exert its effect by an action similar to ACTH. The exact method by which it
acts is unknown as in other drugs used in the disease. Although Page (1) states
that it may reduce the light sensitivity of the skin we had no satisfactory re-
sponse in a few cases of actinic dermatitis which were treated during the sum-
mer. Miller, Herrmann and Rubin (11) are of the opinion that mepacrine neither
sensitizes nor desensitizes a patient to ultra violet light.
STYMMARY
Sixty-two cases of lupus erythematosus were treated by mepacrine (atabrine)
and a comparison made as regards cure, complications and relapses with series
of cases treated by bismuth and mapharside. Mepacrine is not so free from
complications as was first thought, and is a potentially more toxic treatment
than bismuth. Patients with lupus erythematosus appear to be more susceptible
to dermatitis than normal individuals.
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